Sealing problem found in some Redipens

Schering-Plough SOL Limited, which produces the PegIntron Redipen to deliver peginterferon alfa-2b to treat hepatitis C, has told the Hong Kong Department of Health about a sealing defect involving glass cartridges in the system. The product is an alternative to traditional vials and syringes. The company says the defect occurs in about three out of every 20,000 devices. Because it's found in so few devices, the company is proposing to send representatives to all doctor's offices and hospitals involved to inspect their stock of the device. The Health Department gave the plan the go-ahead and Schering-Plough has set up a hotline--3791 2987--for public enquiries. Report

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.